BUSINESS
Daiichi Sankyo Espha Set to Push Drug Adherence for Cancer AGs, Boost Added Value for Generics
Daiichi Sankyo Espha is working to ramp up drug adherence for its authorized generics (AGs) in the oncology arena, while at the same time boosting added values to non-AG generics, which will hold the key as more and more healthcare…
To read the full story
Related Article
- Kentaro Murakawa Named as New President for Daiichi Sankyo Espha
February 26, 2019
BUSINESS
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





